Tens of countless dosages of drugs that President Donald Trump promoted as ” video game changers” in the fight versus the coronavirus are now in limbo after the Fda removed them of their emergency usage authorization today.
The drugs– hydroxychloroquine sulfate and chloroquine phosphate– were considered too dangerous and likely ineffective to treat COVID-19
The FDA’s decision Monday, which one Trump official denounced as a partisan attack, follows a mad dash by states and healthcare facilities to buy chloroquine and hydroxychloroquine after health care service providers were offered a thumbs-up to utilize the drug in March through the emergency situation usage authorization. The drugs were otherwise not authorized to treat COVID-19
” What do we need to lose?” Trump asked in a March 21 news briefing that endorsed the drugs.
Based on continued evaluation of clinical data, FDA has actually figured out that chloroquine and hydroxychloroquine are unlikely to be effective in treating #COVID19 and therefore we are withdrawing the emergency situation usage authorization for these drugs: https://t.co/k9kJMeci0a pic.twitter.com/W2aItvFcBU
— FDA Drug Details (@FDA_Drug_Info) June 15, 2020
Makes by mid-March revealed that they had actually ramped up production of the drugs internationally to fulfill expected demand. Now it’s uncertain what will be done with the excess supply.
The federal stockpile has 66 million dosages of the drugs, according to The New York City Times. This includes 3 million tablets of Resochin, Bayer’s chloroquine phosphate drug, which the business contributed however is not authorized for use in the U.S.
Bayer’s contribution was planned to be utilized “as the government considers suitable,” a Bayer agent informed HuffPost in an e-mail.
The U.S. Department of Health and Human Services ” is working with the companies that donated the hydroxychloroquine sulfate and chloroquine phosphate to identify the available choices for the items that stay,” Stephanie M. Bialek, chief of the Strategic National Stockpile’s Interaction Services Area, told HuffPost Wednesday.
Similar respo